| Literature DB >> 23758654 |
Florence B Gilbert1, Patricia Cunha, Kirsty Jensen, Elizabeth J Glass, Gilles Foucras, Christèle Robert-Granié, Rachel Rupp, Pascal Rainard.
Abstract
Mastitis caused by Escherichia coli and Staphylococcus aureus is a major pathology of dairy cows. To better understand the differential response of the mammary gland to these two pathogens, we stimulated bovine mammary epithelial cells (bMEC) with either E. coli crude lipopolysaccharide (LPS) or with S. aureus culture supernatant (SaS) to compare the transcriptomic profiles of the initial bMEC response. By using HEK 293 reporter cells for pattern recognition receptors, the LPS preparation was found to stimulate TLR2 and TLR4 but not TLR5, Nod1 or Nod2, whereas SaS stimulated TLR2. Biochemical analysis revealed that lipoteichoic acid, protein A and α-hemolysin were all present in SaS, and bMEC were found to be responsive to each of these molecules. Transcriptome profiling revealed a core innate immune response partly shared by LPS and SaS. However, LPS induced expression of a significant higher number of genes and the fold changes were of greater magnitude than those induced by SaS. Microarray data analysis suggests that the activation pathways and the early chemokine and cytokine production preceded the defense and stress responses. A major differential response was the activation of the type I IFN pathway by LPS but not by SaS. The higher upregulation of chemokines (Cxcl10, Ccl2, Ccl5 and Ccl20) that target mononuclear leucocytes by LPS than by SaS is likely to be related to the differential activation of the type I IFN pathway, and could induce a different profile of the initial recruitment of leucocytes. The MEC responses to the two stimuli were different, as LPS was associated with NF-κB and Fas signaling pathways, whereas SaS was associated with AP-1 and IL-17A signaling pathways. It is noteworthy that at the protein level secretion of TNF-α and IL-1β was not induced by either stimulus. These results suggest that the response of MEC to diffusible stimuli from E. coli and S. aureus contributes to the onset of the response with differential leucocyte recruitment and distinct inflammatory and innate immune reactions of the mammary gland to infection.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23758654 PMCID: PMC3686618 DOI: 10.1186/1297-9716-44-40
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Features of bacterial strains shortlisted for stimulation of bMEC
| Newbould 305 | hla+++ hlb+++ | agr1 | CP5 | 20 | 5 | 10 |
| 169.32 | hla+++ hlb+++ | agr2 | CP8 | 120 | 50 | 5 |
| 628.24 | hla- hlb- | agr1 | CP5 | 10 | 0 | 0.6 |
| 644.15 | hla- hlb- | agr1 | CP5 | 5 | 0 | 0.6 |
Hla Alpha hemolysin, hlb Beta hemolysin, CP Capsular polysaccharide, LukS Small component of bi-component leucotoxins. Toxin titers and concentrations were measured in 8-h culture supernatants.
Gene-specific oligonucleotide primers used for qPCR
| 18 s rRNA | F: CGGGGAGGTAGTGACGAAA | 196 | 69 | AF176811 |
| | R: CCGCTCCCAAGATCCAACTA | | | |
| TNFa | F:TCTTCTCAAGCCTCAAGTAACAAGC | 104 | 69 | EU276079 |
| | R: CCATGAGGGCATTGGCATAC | | | |
| Il6 | F: TGCTGGTCTTCTGGAGTATC | 153 | 62 | EU276071 |
| | R: GTGGCTGGAGTGGTTATTAG | | | |
| Ccl2 | F: GCTCGCTCAGCCAGATGCAA | 117 | 62 | NM174006 |
| | R: GGACACTTGCTGCTGGTGACTC | | | |
| Ccl5 | F: CTGCCTTCGCTGTCCTCCTGATG | 217 | 62 | NM175827 |
| | R: TTCTCTGGGTTGGCGCACACCTG | | | |
| Ccl20 | F: TTCGACTGCTGTCTCCGATA | 172 | 62 | NM174263 |
| | R: GCACAACTTGTTTCACCCACT | | | |
| CD83 | F: GAA GGG CAG AGA AAC CTG AC | 231 | 65°C | BC112861 |
| | R : AGA GGT GAC TGG GAG GAA AG | | | |
| Nos2 | F: CTT GAG CGA GTG GTG GAT GG | 240 | 64 | NM001076799 |
| | R: CCT TCA TCC TGG ACG TGG TTC | | | |
| Isg15 | F: CGC-CCA-GAA-GAT-CAA-TGT-GC | | | NM_174366 |
| | R: TCC-TCA-CCA-GGA-TGG-AGA-TG | 158 | 62 | |
| Cxcl10 | F: TTC-AGG-CAG-TCT-GAG-CCT-AC | 218 | 62 | NM_001046551 |
| R: ACG-TGG-GCA-GGA-TTG-ACT-TG |
Figure 1Activity of crude LPS (LPS Sigma) and SaS (SaS N305) on HEK 293 cells transfected with human TLR2, TLR4, TLR5, Nod1 or Nod2. a) Pure LPS (ULPS) and purified LTA were used as agonists of TLR4 and TLR2, respectively. The response of HEK Blue cells (InvivoGen) was measured spectrophotometrically (OD 630 nm). b) Flagellin, C12-iE-DAP and MDP were used as agonists of TLR5, Nod1 and Nod2, respectively. The response of HEK 293 cells was evaluated through secretion of CXCL8, measured by ELISA.
Figure 2Detection of MAMP in SaS and effect on MEC. a) Detection of LTA in SaS. SaS (50 μL) was submitted to SDS-PAGE and immunoblotted with a mAb to LTA (track 1). LTA appeared as a smear owing to its size heterogeneity as a result of varied number of glycerolphosphate units. Immunoblotting was also performed with SaS treated with proteinase K (track 2) or with purified S. aureus LTA (250 ng or 150 ng, tracks 3 and 4). SaS was depleted of LTA with beads coated with mAb to LTA (track 5). High molecular weight bands are the mAb light and heavy chains. SaS treated with control beads without mAb is shown (track 6). b) MEC were incubated for 16 h with SaS (25%) treated with control beads or with mAb-coated beads, and concentrations of CXCL8 in cell culture supernatants measured by ELISA. Purified LTA (250 ng/mL) was added to the depleted SaS to restore activity. c) Staphylococcal protein A (SpA) was detected in SaS and was able to stimulate bMEC. Immunoblot of 8-h N305 SaS revealed with a peroxidase-conjugated rabbit antiserum reacting with SpA; d) bMEC were incubated for 6 h with either recombinant SpA or purified SpA, and CXCL8 concentrations measured in the cell culture supernatant by ELISA. e) Dose–response of bMEC to decreasing concentrations of staphylococcal alpha hemolysin. Bovine MEC were incubated with purified alpha hemolysin for 16 h, and CXCL8 was measured in cell culture supernatant by ELISA. To investigate the heat-resistance of the stimulus, alpha hemolysin was heated at 95°C for 10 min.
Number of differentially expressed genes (DEG) as a function of stimulus and duration of exposure
| Up-regulated | 103 | 104 | 201 | 541 |
| Down-regulated | 7 | 212 | 16 | 273 |
Figure 3Venn diagrams showing differentially expressed genes as a function of time and stimulus. Upper row: all DEG. Lower row: up-regulated annotated genes only. The lists of the sets of genes up-regulated on exposure to both SaS and LPS are given. Venn diagrams composed with VENNY [38]. List of the 16 upregulated annotated genes shared in LPS 3 h and SaS 3 h: CCL20, CXCL8, IL6, CD83, CXCL1, NFKBIA, CXCL3, BIRC3, SLCO4A1, PLAUR, IER3, ARRDC4, CEBPD, SGK1, BTG3, GABARAPL1. List of the 22 upregulated annotated genes shared in LPS 6 h and SaS 6 h: CCL20, CXCL8, CXCL5, NOS2A, CCL2, CXCL2, CFB, SGK1, NFKBIA, CD83, ARRDC4, SLC25A28, SAT1, IKBKAP, GABARAPL1, CALCOCO2, PLAUR, LEPROT, DUSP1, TLR4, CEBPD, SNRNP27.
Genes most significantly differentially expressed by bMEC stimulated by LPS for 3 and 6 h compared to unstimulated cells, ordered by functional classes
| | | ||
| NFKBIA | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 3.60 | 4.53 |
| BIRC3 | Baculoviral IAP repeat-containing protein 3 | 3.10 | 3.19 |
| ZNFX1 | NFX1-type zinc finger-containing protein 1 | | 3.11 |
| ZNHIT3 | Zinc finger HIT domain-containing protein 3 | 2.48 | 3.08 |
| IKBKAP | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein | 2.52 | 2.33 |
| TRIM21 | Tripartite motif-containing protein 21 | 1.61 | 2.26 |
| CEBPD | CCAAT/enhancer binding protein (C/EBP), delta | 2.02 | 1.60 |
| NFKB2 | Nuclear factor of κ light polypeptide gene enhancer in B-cells 2 | 1.78 | 1.94 |
| JAK2 | Janus kinase 2 | 1.90 | 1.85 |
| DUSP1 | Dual specificity phosphatase 1 | | 1.85 |
| FOS | V-fos | | -2.01 |
| PLK2 | Serum-inducible kinase, transcript variant 1,PLK2 | -1.50 | |
| | | ||
| CCL5 | RANTES | 7.10 | 20.52 |
| CCL20 | Chemokine (C-C motif) ligand 20 | 19.42 | 19.37 |
| CXCL8 | Chemokine (C-X-C motif) ligand 8, Interleukin-8 | 8.53 | 13.96 |
| CXCL5 | Chemokine (C-X-C motif) ligand | 4.75 | 7.96 |
| CCL2 | Chemokine (C-C motif) ligand 2 | | 6.38 |
| CXCL2 | Chemokine (C-X-C motif) ligand 2 | | 5.06 |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 | 4.93 | |
| IL6 | Interleukin 6 | 6.64 | 4.85 |
| CXCL3 | Chemokine (C-X-C motif) ligand 3 | 3.15 | 3.60 |
| IL1B | Interleukin 1, beta | 5.01 | 3.32 |
| IFNB | Interferon beta precursor | 4.89 | 3.25 |
| TNFSF13B | Tumor necrosis factor (ligand) superfamily, member 13 (BAFF) | 2.96 | |
| IL2 | Interleukin 2 | 4.30 | 2.86 |
| CCL16 | Chemokine (C-C motif) ligand 16 | 2.60 | 2.77 |
| CSF2 | Colony stimulating factor 2 (granulocyte-macrophage) | 1.69 | 2.10 |
| IL23A | Interleukin 23, alpha subunit p19 | | 2.06 |
| CTGF | Connective tissue growth factor | -1.92 | |
| TGFB2 | Transforming growth factor beta-2 precursor | | -1.46 |
| | | ||
| IFIT3 | Interferon-induced protein with tetratricopeptide repeats 3 | 3.02 | 7.92 |
| MX1 | Myxovirus (influenza virus) resistance 1 | 1.84 | 2.93 |
| IFIH1 | Interferon induced with helicase C domain 1 | 2.65 | 4.10 |
| ISG15 | ubiquitin-like modifier | 2.46 | 3.69 |
| GBP1 | Interferon-induced guanylate-binding protein 1 | 2.17 | 3.56 |
| TNFSF10 | Tumor necrosis factor ligand superfamily member 10 (TRAIL) | 2.02 | 3.13 |
| IFI44 | Similar to Interferon-induced protein 44 | | 3.23 |
| OAS1 | 2′-5′-oligoadenylate synthetase 1 | 1.61 | 3.15 |
| IFI27L1 | Interferon alpha-inducible protein 27-like protein 1 | | 2.88 |
| IRF7 | Interferon regulatory factor 7 | 1.45 | 2.75 |
| TRIM21 | Tripartite motif-containing protein 21 | 1.61 | 2.26 |
| GVIN1 | GTPase, very large interferon inducible 1 | | 2.21 |
| STAT2 | Signal transducer and activator of transcription 2 | | 2.01 |
| STAT1 | Signal transducer and activator of transcription 1 | | 1.96 |
| IRF2 | Interferon regulatory factor 2 | | 1.84 |
| | | ||
| NOS2A | Nitric oxide synthase 2A (inducible) | 5.57 | 7.45 |
| S100A8 | Calcium-binding protein A8, calgranulin A | 2.87 | 7.00 |
| CFB | Complement factor B | 3.39 | 5.02 |
| S100A9 | Calcium-binding protein A9, calgranulin B | 2.40 | 4.59 |
| CD83 | Cell surface protein HB15 | 5.50 | 3.40 |
| C2 | C2 Complement component 2 | 1.79 | 2.64 |
| ICAM1 | Intercellular adhesion molecule 1 | 2.50 | |
| LTF | Lactotransferrin | | 2.47 |
| PLAT | Plasminogen activator, tissue type | 1.93 | 2.11 |
| PLAUR | Urokinase plasminogen activator surface receptor | 2.11 | 1.96 |
| CAMP | Cathelicidin antimicrobial peptide | | 1.89 |
| TLR4 | Toll-like receptor 4 | 1.62 | 1.81 |
| MMP9 | Matrix metallopeptidase 9 | | 1.77 |
| CD74 | Major histocompatibility complex, class II invariant chain | | 1.75 |
| BNBD10 | Beta-defensin 10 | 1.59 | 1.67 |
| | | ||
| SOD2 | Superoxide dismutase 2 | 3.19 | 5.05 |
| SGK1 | Serum/glucocorticoid regulated kinase 1 | 1.81 | 4.79 |
| PARP14 | Poly (ADP-ribose) polymerase family, member 14 | | 2.95 |
| | | ||
| IGFBP3 | Insulin-like growth factor binding protein-3 | 2.38 | 5.27 |
| EIF4E | Translation initiation factor 4E | 2.32 | 5.20 |
| CASP4 | Caspase-4 Precursor | 1.60 | 3.04 |
| CASP8 | Caspase-8 precursor | 1.58 | 2.29 |
| IER3 | Immediate early response 3 | 2.09 | |
| TNFRSF6 | TNF receptor superfamily, member 6 (FAS) | 1.82 | 1.86 |
| CDK2AP1 | Cyclin-dependent kinase 2 associated protein 1 | | -1.66 |
| EI24 | Etoposide-induced protein 2.4 homolog | -1.65 | |
Genes most significantly differentially expressed by bMEC stimulated by SaS for 3 and 6 h compared to unstimulated cells, ordered by functional classes
| | | ||
| FOS | Proto-oncogene protein c-fos | 2.09 | 2.21 |
| NFKBIA | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 2.15 | 2.07 |
| DUSP1 | dual specificity phosphatase 1 | 1.91 | 1.71 |
| ETS2 | erythroblastosis virus E26 oncogene homolog 2 (avian) | | 1.72 |
| CEBPD | CCAAT/enhancer binding protein (C/EBP), delta | 1.65 | 1.59 |
| SQSTM1 | sequestosome 1 | | 1.58 |
| BIRC3 | Baculoviral IAP repeat-containing 3 | 1.56 | |
| IKBKAP | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein | | 1.49 |
| JUN | Jun oncogene | 1.57 | 1.47 |
| NFKB2 | nuclear factor of κ light polypeptide gene enhancer in B-cells 2 | -2.05 | |
| FUS | RNA-binding protein FUS | | -1.82 |
| SFRS3 | Splicing factor, arginine/serine-rich 3 | | -1.71 |
| SFPQ | splicing factor proline/glutamine-rich | | -1.59 |
| RABL3 | RAB, member of RAS oncogene family-like 3 | | -1.57 |
| U2AF1 | Splicing factor U2AF | | -1.54 |
| CSTF2 | cleavage stimulation factor, 3′pre-RNA, subunit 2 | | -1.53 |
| RDBP | RNA-binding protein RD, Negative elongation factor E | | -1.47 |
| DKC1 | dyskeratosis congenita 1, dyskerin | | -1.47 |
| CRSP9 | Cofactor required for Sp1 transcriptional activation subunit 9 | -1.45 | |
| | | ||
| CXCL8 | Chemokine (C-X-C motif) ligand 8, Interleukin-8 | 6.20 | 4.52 |
| CCL20 | chemokine (C-C motif) ligand 20 | 4.94 | 4.27 |
| CXCL1 | Chemokine (C-X-C motif) ligand 1 | 3.51 | |
| CXCL3 | Chemokine (C-X-C motif) ligand 3 | 2.48 | |
| CCL2 | chemokine (C-C motif) ligand 2 | 2.22 | 2.71 |
| CXCL5 | chemokine (C-X-C motif) ligand 5 | | 2.57 |
| CXCL2 | chemokine (C-X-C motif) ligand 2 | | 2.47 |
| IL6 | Interleukin 6 | 1.71 | |
| VEGFB | Vascular endothelial growth factor B Precursor | | 1.47 |
| | | ||
| PLAUR | urokinase plasminogen activator surface receptor | 1.70 | 2.46 |
| LBP | lipopolysaccharide binding protein | | 2.26 |
| NOS2A | Nitric oxide synthase 2A (inducible) | | 2.05 |
| CD83 | Cell surface protein HB15 | 1.89 | 1.73 |
| CFB | complement factor B | | 1.70 |
| SQSTM1 | sequestosome 1 | | 1.58 |
| TLR4 | toll-like receptor 4 | | 1.50 |
| ILRAP | interleukin 1 receptor accessory protein | | 1.44 |
| CD96 | Cell surface antigen CD96 | | 1.31 |
| C3 | Complement factor 3 | | -1.35 |
| MMP9 | Matrix metallopeptidase 9 | -1.33 | |
| | | ||
| SGK1 | serum/glucocorticoid regulated kinase 1 | 1.73 | 1.75 |
| | | ||
| IER3 | immediate early response 3 | 1.99 | 1.58 |
| RASSF1 | Ras association domain-containing protein 1 | | 1.52 |
| CDKN2B | cyclin-dependent kinase inhibitor 2B | | -1.85 |
| CDC20 | cell division cycle 20 homolog (S. cerevisiae) | | -1.60 |
| CCNA2 | cyclin A2 | -1.37 | |
Functional pathways of genes most affected by LPS stimulation, determined by using the Genomatix Pathway System (GePS)
| | | |
|---|---|---|
| | | |
| Fas signaling pathway | 7.58 × 10-6 | 5/20 |
| nb of genes | ||
| NF kappa B | 1.52 × 10-12 | 41/1542 |
| Signal transducer and activator of transcription | 1.76 × 10-12 | 36/1184 |
| Toll like receptor | 2.49 × 10-12 | 26/593 |
| Apoptosis | 7.27 × 10-12 | 52/2592 |
| Tumor protein p53 | 8.23 × 10-12 | 34/1108 |
| Interleukin 1 | 2.05 × 10-11 | 27/706 |
| Janus kinase | 2.57 × 10-11 | 26/657 |
| Tumor necrosis factor | 5.10 × 10-11 | 34/1182 |
| Interleukin 6 | 5.57 × 10-11 | 26/680 |
| Inflammatory | 8.31 × 10-11 | 33/1133 |
| Nuclotide oligodimerization domain/ | 9.52 × 10-11 | 13/131 |
| Caspase recruitment protein family | | |
| | | |
| Cytokine receptor binding | 2.29 × 10-9 | 12/187 |
| Receptor binding | 9.83 × 10-9 | 23/917 |
| Cytokine activity | 5.22 × 10-8 | 11/199 |
| Chemokine activity | 4.88 × 10-7 | 6/47 |
| Chemokine receptor binding | 9.02 × 10-7 | 6/52 |
| | | |
| Immune system process | 2.27 × 10-11 | 28/1094 |
| Immune response | 2.98 × 10-10 | 22/736 |
| Locomotion | 2.72 × 10-9 | 19/605 |
| Multi-organism process | 8.37 × 10-9 | 21/800 |
| Response to chemical stimulus | 1.67 × 10-8 | 28/1461 |
| | | |
| | | |
| Signal transducer and activation | 8.41 × 10-17 | 44/1184 |
| NF-kB | 2.66 × 10-16 | 49/1542 |
| Chemokine (CC motif) ligand 2 | 8.63 × 10-16 | 23/272 |
| Interleukin 6 | 1.91 × 10-15 | 33/680 |
| Toll like receptor | 2.39 × 10-15 | 31/593 |
| Immune | 4.25 × 10-15 | 38/957 |
| Inflammatory | 4.85 × 10-15 | 41/1133 |
| Tumor necrosis factor | 2.14 × 10-14 | 41/1182 |
| Interleukin 1 | 2.87 × 10-13 | 31/706 |
| Janus kinase | 2.89 × 10-13 | 30/657 |
| | | |
| Cytokine activity | 1.21 × 10-10 | 14/199 |
| Receptor binding | 3.74 × 10-9 | 25/917 |
| Cytokine receptor binding | 7.90 × 10-9 | 12/187 |
| Protein binding | 5.75 × 10-6 | 80/8067 |
| | | |
| Immune response | 1.59 × 10-14 | 29/736 |
| Immune system process | 3.15 × 10-13 | 33/1094 |
| Response to stress | 1.53 × 10-12 | 42/1880 |
| Defense response | 2.45 × 10-12 | 26/708 |
| Response to stimulus | 2.98 × 10-11 | 58/3713 |
* Nb of genes: number of genes in the list/number of genes in the pathway.
Functional pathways of genes most affected by SaS stimulation, determined by using the Genomatix Pathway System (GePS)
| | | |
|---|---|---|
| | | |
| AP-1 transcription factor network | 5.05 × 10-7 | 6/69 |
| | | |
| Interleukin 17A | 8.75 × 10-7 | 7/137 |
| Protein kinase B | 1.59 × 10-6 | 9/297 |
| Baculoviral IAP repeat containing protein, | 1.94 × 10-6 | 9/304 |
| apoptosis inhibitor | | |
| FBJ murine osteosarcoma viral oncogene | 6.49 × 10-6 | 4/32 |
| homolog B | | |
| Cyclin D1 | 7.69 × 10-6 | 10/461 |
| Chemokine (CC motif) ligand 2 | 8.40 × 10-6 | 8/272 |
| | | |
| Too few genes, | | |
| | | |
| Too few genes, | | |
| | | |
| | | |
| Too few genes, | | |
| | | |
| Minichromosome maintenance complex | 6.13 × 10-7 | 7/42 |
| Cyclin B1 | 9.29 × 10-7 | 10/112 |
| Cyclin D1 | 2.34 × 10-6 | 19/461 |
| DNA repair | 4.43 × 10-6 | 23/725 |
| Cyclin A2 | 4.37 × 10-6 | 11/167 |
| Checkpoint | 2.51 × 10-5 | 16/402 |
| Interleukin 17A | 4.07 × 10-5 | 10/137 |
| Nuclear receptor subfamily 3, group C | 4.08 × 10-5 | 10/171 |
| Cell cycle | 4.94 × 10-5 | 32/1309 |
| Aryl hydrocarbon receptor | 9.93 × 10-5 | 10/190 |
| | | |
| Protein binding | 2.95 × 10-5 | 100/8067 |
| Protein heterodimerizaton activity | 1.23 × 10-4 | 9/202 |
| Oxidoreductase activity | 2.39 × 10-4 | 17/685 |
| | | |
| Symbiosis, encompassing mutualism | 2.15 × 10-5 | 6/58 |
| Viral reproduction | 3.84 × 10-5 | 7/94 |
| Cell death | 1.05 × 10-4 | 27/1275 |
| Death | 1.10 × 10-4 | 27/1279 |
| Response to organic substance | 1.24 × 10-4 | 21/874 |
| Oxidation reduction | 1.98 × 10-4 | 17/645 |
Figure 4Analysis by RT-qPCR of the expression of a set of genes showing differential expression in the microarray analysis. Relative quantification of the TNFa, IL6, Ccl2, Ccl5, Ccl20, Nos2 and CD83 transcripts by RT-qPCR 3 h or 6 h after stimulation of bMEpC with LPS or SaS. Median values (Q1 and Q3) from bMEpC of five cows are shown. * Statistical significance relative to Control. § Statistical significance, LPS versus SaS.
Figure 5Effect of IFN-β alone or in combination with SaS on the expression of IFN-inducible genes by bMEC. a) Response of bMEC to increasing concentrations of recombinant human IFN-β. After 3 or 6 h of incubation with IFN-β, the relative expression of the Cxcl10 and Isg15 genes was determined by RT-qPCR. b) Effect of adding IFN-β (10 ng/mL) to SaS after 3 h of exposure to SaS, and comparison with the effect on Cxcl10 and Isg15 expression of SaS and LPs alone, measured 3 h after addition of IFN-β. c) Effect of adding IFN-β as in b) on the expression of Ccl5, Ccl2 and Nos2a. * P < 0.05, relative to Medium; $ P < 0.05, LPS versus SaS.
Figure 6Main signaling pathways supposed to be activated in MEC exposed to either crude LPS (a) or culture supernatant (b). Crude LPS (a simplified substitute of outer membrane vesicles, omv) is sensed by both TLR2 and TLR4, which activates the NF-κB pathway by the MyD88-dependent pathway. In addition, the TRAM-TRIF-IRF3 pathway leads to the activation of genes that have an IRF-binding site in their promoter sequence. S. aureus culture supernatant (SaS) is sensed by TLR2 and other unidentified receptors that activate the NF-κB and AP-1 pathways. As a result, E. coli stimulation induces a higher number of genes (IFN-stimulated genes) than does S. aureus stimulation. This is exemplified by the overexpression of a panel of chemokine genes that have the potential to recruit a greater variety of leukocytes (see text). LTA: lipoteichoic acid; MyD88: myeloid differentiation primary-response gene 88; TRIF: TIR-domain-containing adaptor protein inducing IFN-β; TRAM: TRIF related adaptor molecule; IFR3: IFN regulatory factor 3; IRFBS: IRF-binding site; JNK: Janus kinase; AP-1: activator protein 1, composed of the Jun and Fos proteins.